Co-Diovan 332.5 - Novartis

Combination of two substances: Valsartan is distinguished by its tolerability and safety, with a side effect profile similar to placebo. Unlike ACE inhibitors, it lacks associated adverse effects like cough or angioedema. Studies reveal its ability to lower urinary oxidative stress markers and reduce oxidative damage in various tissues. These findings suggest valsartan’s potential as a therapeutic tool for patients with heightened oxidative stress and protein glycation, offering benefits that extend beyond its established antihypertensive effects. Hydrochlorothiazide (HCTZ) poses a significant risk for squamous cell carcinoma (SCC) in transplant recipients, doubling their likelihood of developing this aggressive skin cancer. Basal cell carcinoma (BCC) shows no such association, but the findings emphasize the need for vigilant monitoring and safer hypertension management options.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Co-Diovan 332.5 by Novartis, consult with your doctor or healthcare professional.